David S. Kabakoff

Filings by David S. Kabakoff span 3 companies, the busiest being Castle Biosciences Inc, Intermune Inc and Trius Therapeutics Inc. In total, 62 filings cover trades dated from 6 August 2010 to 17 June 2021.

In open-market terms, that means 2 purchases worth €1.0M on one side and 41 sales worth €56.1M on the other. The net balance comes to €55.1M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 2 share grants and 6 option exercises. So far in 2021, the count stands at no purchases and 15 sales.

Most recently, on 21 June 2021, the filings show an open-market sale worth €1.9M in Castle Biosciences Inc. The clock since the last published purchase (31 July 2019) now reads 2,641 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.